USPTO serial 79352105
ULTIMÉ
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- WOLD, BARBARA NIELSEN
- Law office
- TMO LAW OFFICE 114 - EXAMINING ATTORNEY ASSIGNED
What this means
These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.
Need help with ULTIMÉ?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Antioxidants (dietary supplements); antibiotic food supplements for animals; nutritional supplements; vitamin supplements; vitamin supplements for animals; capsules for pharmaceutical purposes; eucalyptus for pharmaceutical purposes; flaxseed for pharmaceutical purposes; gallic acid for pharmaceutical purposes; lactose for pharmaceutical purposes; meal for pharmaceutical purposes; moisturising body lotion (pharmaceutical); moisturising creams (pharmaceutical); moisturising gels (pharmaceutical); moisturising lotions (pharmaceutical); moisturising skin creams (pharmaceutical); moisturising skin lotions (pharmaceutical); oils for pharmaceutical purposes; pain killers (pharmaceuticals); pharmaceutical compound eye-drops; pharmaceutical anticoagulant preparations; pharmaceutical appetite suppressants; pharmaceutical compositions; pharmaceutical creams; pharmaceutical cytostatic preparations; pharmaceutical cytostatic preparations for use in parenteral form; pharmaceutical drugs; pharmaceutical drugs being a positive inotropic agent; pharmaceutical lipsalves; pharmaceutical medicaments in unit dosage form; pharmaceutical preparations; pharmaceutical preparations being antacids; pharmaceutical preparations being antiulceratives; pharmaceutical preparations being hormone preparations for human use; pharmaceutical preparations containing a vasodilator; pharmaceutical preparations containing amino acids; pharmaceutical preparations containing calcitonin; pharmaceutical preparations containing coagulants; pharmaceutical preparations containing enzymes; pharmaceutical preparations containing essential oils; pharmaceutical preparations containing fish oil; pharmaceutical preparations containing fluoride for prevention of dental decay; pharmaceutical preparations containing hormones for humans; pharmaceutical preparations containing royal jelly; pharmaceutical preparations containing vitamins; pharmaceutical preparations for alleviating disorders of the brain; pharmaceutical preparations for animals; pharmaceutical preparations for application to the skin; pharmaceutical preparations for assisting the prevention of bone diseases; pharmaceutical preparations for enteral administration; pharmaceutical preparations for growing eyebrows; pharmaceutical preparations for growing eyelashes; pharmaceutical preparations for health care; pharmaceutical preparations for human use; pharmaceutical preparations for nasal use; pharmaceutical preparations for oral use; pharmaceutical preparations for personal use; pharmaceutical preparations for promoting the maturation of the cervix; pharmaceutical preparations for skin care; pharmaceutical preparations for the preservation and storage of human organs; pharmaceutical preparations for the prevention of bone conditions; pharmaceutical preparations for the prevention of cardiovascular disorders; pharmaceutical preparations for the relief of insect bites; pharmaceutical preparations for the relief of insect stings; pharmaceutical preparations for the therapeutic treatment of diabetes mellitus; pharmaceutical preparations for the topical treatment of dermatological disorders; pharmaceutical preparations for the treatment of alcoholism; pharmaceutical preparations for the treatment of blackheads; pharmaceutical preparations for the treatment of blood disorders; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of cardiovascular diseases; pharmaceutical preparations for the treatment of cardiovascular disorders; pharmaceutical preparations for the treatment of depressive illness; pharmaceutical preparations for the treatment of dermatological disorders; pharmaceutical preparations for the treatment of digestive maladies; pharmaceutical preparations for the treatment of disorders of the central nervous system; pharmaceutical preparations for the treatment of disorders of the gastro-enterological tract; pharmaceutical preparations for the treatment of dyslexia; pharmaceutical preparations for the treatment of gastric diseases; pharmaceutical preparations for the treatment of gastrointestinal disorders; pharmaceutical preparations for the treatment of gynaecological disorders; pharmaceutical preparations for the treatment of joint related diseases; pharmaceutical preparations for the treatment of pimples; pharmaceutical preparations for the treatment of premenstrual tension; pharmaceutical preparations for the treatment of psoriasis; pharmaceutical preparations for the treatment of psoriasis in human beings; pharmaceutical preparations for the treatment of spots; pharmaceutical preparations for the treatment of the eyes; pharmaceutical preparations for topical use; pharmaceutical preparations for treating dandruff; pharmaceutical preparations for treating sunburn; pharmaceutical preparations for use as laxative; pharmaceutical preparations for use in dentistry; pharmaceutical preparations for use in discouraging the smoking habit; pharmaceutical preparations for use in gynaecology; pharmaceutical preparations for use in hypercholesterolemia therapy; pharmaceutical preparations for use in the treatment of arthritis; pharmaceutical preparations for use in the treatment of arthrosis; pharmaceutical preparations for use in the treatment of colostomy patients; pharmaceutical preparations for use in the treatment of diseases of the vertebral column; pharmaceutical preparations for use in the treatment of hormonal disorders; pharmaceutical preparations for use in the treatment of ileostomy patients; pharmaceutical preparations for use in the treatment of lumbago; pharmaceutical preparations for use in the treatment of muscle tension; pharmaceutical preparations for use in the treatment of pimples; pharmaceutical preparations for use in the treatment of rheumatism; pharmaceutical tablets; pharmaceutical sweets; pharmaceutical substances; plant extracts for pharmaceutical purposes; plant extracts for pharmaceutical use; pharmaceutical tonic preparations; propolis for pharmaceutical purposes; skincare preparations (pharmaceutical); sprays for use on the body (pharmaceuticals); yeast extracts for pharmaceutical purposes; yeast for pharmaceutical purposes | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jan 25, 2025 | FINT | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Jan 4, 2025 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Jan 4, 2025 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Apr 1, 2024 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Mar 13, 2024 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Mar 13, 2024 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Jan 3, 2024 | MAB2 | ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Jan 3, 2024 | MAB2 | ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Jan 3, 2024 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Jul 10, 2023 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jun 17, 2023 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jun 17, 2023 | RFRR | REFUSAL PROCESSED BY MPU | — |
| May 9, 2023 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| May 8, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 4, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 18, 2022 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Oct 14, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Oct 13, 2022 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |